David A. Siegel Akero Therapeutics, Inc. Transaction History

Two Sigma Advisers, LP

$43.8 Billion
Q2 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 18,100 shares of AKRO stock, worth $487,976. This represents 0.0% of its overall portfolio holdings.

Number of Shares

18,100

Holding current value

$487,976

% of portfolio

0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$18.31 - $24.62 $331,411 - $445,622	18,100 New	18,100 $424,000
Q1 2023 May 15, 2023	SELL	$37.27 - $50.24 $108,083 - $145,696	-2,900 Reduced 13.74%	18,200 $696,000
Q4 2022 Feb 14, 2023	BUY	$33.44 - $54.8 $705,584 - $1.16 Million	21,100 New	21,100 $1.16 Million
Q2 2022 Aug 15, 2022	SELL	$8.0 - $15.01 $19,200 - $36,024	-2,400 Reduced 9.76%	22,200 $210,000
Q1 2022 May 16, 2022	SELL	$12.97 - $22.26 $186,768 - $320,544	-14,400 Reduced 36.92%	24,600 $349,000
Q4 2021 Feb 14, 2022	SELL	$19.87 - $26.24 $822,618 - $1.09 Million	-41,400 Reduced 51.49%	39,000 $825,000
Q3 2021 Nov 15, 2021	SELL	$18.65 - $25.46 $1.12 Million - $1.53 Million	-59,900 Reduced 42.69%	80,400 $1.8 Million
Q2 2021 Aug 16, 2021	SELL	$24.81 - $32.35 $729,414 - $951,090	-29,400 Reduced 17.32%	140,300 $3.48 Million
Q1 2021 May 17, 2021	BUY	$24.04 - $34.19 $863,036 - $1.23 Million	35,900 Added 26.83%	169,700 $4.92 Million
Q4 2020 Feb 16, 2021	BUY	$25.12 - $29.89 $3.06 Million - $3.64 Million	121,900 Added 1024.37%	133,800 $3.45 Million
Q3 2020 Nov 16, 2020	BUY	$30.79 - $39.92 $366,401 - $475,048	11,900 New	11,900 $366,000

Others Institutions Holding AKRO

# of Institutions

168

Shares Held

72.7M

Call Options Held

178K

Put Options Held

164K

View Full List

About Akero Therapeutics, Inc.

Ticker AKRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,417,600
Market Cap $1.25B
Description
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...

More about AKRO

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account